Status:
COMPLETED
Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal
Lead Sponsor:
Atea Pharmaceuticals, Inc.
Conditions:
Healthy Volunteer Study
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 following oral administration under fasting conditions or with a meal in healthy adult subjects
Eligibility Criteria
Inclusion
- Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug
- Females must have a negative pregnancy test at Screening and prior to dosing
- Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/m2
- Willing to comply with the study requirements and to provide written informed consent
Exclusion
- Pregnant or breastfeeding
- Infected with hepatitis B virus, hepatitis C virus, HIV or COVID-19
- Abuse of alcohol or drugs
- Use of other investigational drugs within 28 days of dosing
- Other clinically significant medical conditions or laboratory abnormalities
Key Trial Info
Start Date :
February 22 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 23 2022
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT05256732
Start Date
February 22 2022
End Date
August 23 2022
Last Update
October 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Atea Study Site
Québec, Montreal, Quebec, Canada